Signature is a translational oncology and genomics company that develops large biobanks in multiple cancers including colorectal and lung cancer in
the framework of multicenter prospective clinical studies.

The longitudinal plasma samples from these biobanks are used to develop and validate next generation (NGS) assays that can applied for the monitor-
ing of patients with late stage cancers using the liquid biopsy concept. Signature believes that focused and high-quality NGS assays have the capacity to become cost effective diagnostic tools for monitoring cancer patients.